Trial Profile
A Phase II Study of Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Oct 2022
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 01 Oct 2022 Results (n=14)by obtaining blood samples from NCT02756897; elucidating the proteomic landscape during therapy, published in the Clinical Lymphoma, Myeloma & Leukemia
- 15 Mar 2022 Status changed from recruiting to active, no longer recruiting.
- 10 Jan 2022 Status changed from active, no longer recruiting to recruiting.